An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data Source

CompletedOBSERVATIONAL

Enrollment

767

Participants

Timeline

Start Date

December 7, 2020

Primary Completion Date

May 6, 2021

Study Completion Date

May 6, 2021

Conditions

Plaque Psoriasis

Interventions

OTHER

Secukinumab

Included patients treated with Cosentyx (Secukinumab) in a retrospective analysis of the BADBIR data source

Trial Locations (1)

Novartis Investigative Site, East Hanover